Insight

UCI Health Launches the First U.S. Trial of Riluzole for ‘Chemo Brain’ in Cancer Patients

Alexandre Chan/LinkedIn

Jun 20, 2025, 14:03

UCI Health Launches the First U.S. Trial of Riluzole for ‘Chemo Brain’ in Cancer Patients

UCI School of Pharmacy and Pharmaceutical Sciences shared a post on LinkedIn:

“In the Media: The UCI Health Chao Family Comprehensive Cancer Center has launched the first U.S. clinical trial to investigate the impact of riluzole therapy on circulating levels of a key brain protein in cancer patients who have experienced treatment-related cognitive impairment, also known as ‘chemo brain’ or ‘brain fog.’

‘Chemo brain is a common thing I see in clinic. My focus is on helping patients feel better. It’s not just about curing their cancer. If we want them to really survive, it’s also about bringing them back to where they were, to recover from these cognitive changes,’ says Alexandre Chan, PharmD, MPH, FCCP, FISOPP, BCPS, BCOP, APh.”

Read further.

Alexandre Chan, Founding Chair and Professor of Clinical Pharmacy Practice at UCI School of Pharmacy and Pharmaceutical Sciences, shared this post, adding:

“Happy to announce that our chemobrain clinical trial at UCI Health Chao Family Comprehensive Cancer Center is currently actively recruiting!”

More posts featuring Alexandre Chan.

Alexandre Chan brain fog cancer chemo brain OncoDaily Oncology riluzole UCI Health Chao Family Comprehensive Cancer Center UCI School of Pharmacy and Pharmaceutical Sciences

Oncologist Near Me – Razelle Kurzrock: Revolutionizing Cancer Treatment Through Precision Medicine

Smoking and Bladder Cancer: What You Need to Know to Protect Yourself

Cervical Cancer Screening: Who Needs a Pap Smear or HPV Test and When?

Clinical Trials in Cancer Care: What They Are, How to Join, and What to Expect

Linda Evangelista and Breast Cancer: How She Went Against, How She Survived, and More